0001213900-26-057887
SEC filingProfusa's Q1 FY2026 results reflect sharply wider operating losses and cash burn as the company advances toward commercialization.
Profusa's operating loss for Q1 FY2026 was -$4.0 million, compared to -$583.6 thousand in the prior-year period. The increase was driven by higher research and development expenses and general and administrative costs as the company scales its operations toward commercialization. The company continues to invest in clinical activities and commercial readiness, which are reflected in the elevated spending levels.
On March 11, 2026, the company terminated its Bitcoin treasury reserve strategy to focus on capital allocation priorities. Management expects that cash on hand, remaining borrowing capacity from the PIPE Investment, proceeds from the ELOC, and Ascent PIPE Notes will provide sufficient funding to support initial commercial operations. However, the company has incurred recurring losses and expects to continue to incur losses and negative operating cash flows until it successfully commences sustainable commercial operations. If adequate funds are not available, the company may need to reconsider production investments, the pace of production ramp-up, expansion plans, or limit research and development activities.